Kraig Biocraft Laboratories Unveils Groundbreaking Scientific Achievement Based on Caddisfly Silk Proteins
Caddisflies (known in the Pacific Northwest as 'Periwinkles') are known for their extraordinary ability to spin silk underwater, which they use to construct protective cases in aquatic environments. By leveraging the unique mechanical and chemical attributes of caddisfly silk proteins, Kraig Labs seeks to engineer materials with unprecedented functionality. This new silk offers the potential for increased durability when submerged in water. Possible applications for this new silk are vast, with exciting potentials for medical adhesives, biomedical textiles, performance apparel, and next-generation fiber technologies.
'This achievement demonstrates our ability to extend beyond spider silk proteins and explore the broader possibilities of silk engineering,' said CEO and Founder of Kraig Labs, Kim Thompson. 'By tapping into the evolutionary diversity of silk-producing organisms, we're expanding the toolkit for creating super fibers that meet the demands of tomorrow's industries.'
The introduction of caddisfly-based transgenic fiber represents a critical milestone in the Company's vision to create new super materials blending the physical and chemical properties of various silk proteins. The result is an ever-growing portfolio of high-performance materials designed to redefine the standards of strength, elasticity, and functionality. These new fibers will leverage the Company's propriety silkworm-based production system to bring these materials to market.
'Incorporating the unique and incredible adhesive properties of caddisfly silk protein has been a key part of the R&D roadmap I laid out when founding Kraig Labs,' Thompson continued. 'Unveiling this pivotal scientific milestone, our first caddisfly-based transgenic, marks not only a significant leap forward for the Company's business model but also a deeply gratifying achievement for me personally and for our team.'
This breakthrough would not have been possible without the dedication and ingenuity of the Company's scientific team. Their relentless pursuit of excellence and creative problem-solving have once again positioned Kraig Labs at the forefront of biotechnological innovation.
'Our team's success with this caddisfly-inspired material is a testament to the power of combining cutting-edge science with bold vision,' added the Company's COO, Jon Rice. 'We are excited about the potential this fiber holds and the new opportunities it creates across multiple sectors.'
Kraig Labs is committed to pushing the boundaries of creativity and science in silk protein engineering. The Company has filed a provisional utility patent application for this exciting new technology. By exploring and integrating the diverse properties of silk from various species, the Company will continue to lead the charge in developing sustainable, high-performance materials that address real-world challenges.
For details about other recent advancements that Kraig Labs has made, please watch the Company's investor conference at www.kraiglabs.com/videos or on the Company's YouTube Channel https://www.youtube.com/@kraigbiocraftlaboratories2270.
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. ( www.KraigLabs.com), a reporting biotechnology company is the leading developer of genetically engineered spider silk-based fiber technologies.
The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company's future and expectations other than historical facts are 'forward-looking statements.' These statements are made on the basis of management's current views and assumptions. As a result, there can be no assurance that management's expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as 'believes,' 'plans,' 'expects,' 'anticipates,' 'foresees,' 'estimated,' 'hopes,' 'if,' 'develops,' 'researching,' 'research,' 'pilot,' 'potential,' 'could' or other words or phrases of similar import. Forward looking statements include descriptions of the Company's business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Trump's Pay-For-Play Chips Deal Generates Alarm and Optimism
(Bloomberg) -- President Donald Trump's controversial plan to take a cut of revenue from chip sales to China is leading to concerns that the US government will find new ways to start charging companies for a range of business activities with other countries. Experts and people familiar with the matter said the surprise deal, in which Nvidia Corp. and Advanced Micro Devices Inc. agreed to pay 15% of their revenues from Chinese AI chip sales to the US, potentially provides a path to enter the Chinese market despite severe export controls, tariffs and other trade barriers. The US-Canadian Road Safety Gap Is Getting Wider Sunseeking Germans Face Swiss Backlash Over Alpine Holiday Congestion To Head Off Severe Storm Surges, Nova Scotia Invests in 'Living Shorelines' Five Years After Black Lives Matter, Brussels' Colonial Statues Remain For Homeless Cyclists, Bikes Bring an Escape From the Streets The question that companies must now confront is whether the risk is worth taking. People familiar with the matter, who asked not to be identified discussing private deliberations, said companies are struggling to figure out what the president's order means for their future, especially given the unpredictable nature of Trump's decision-making. 'This is truly bizarre and unusual, and the troubling thing — beyond the individual instances of AMD and Nvidia — is the possibility that this will be expanded,' said Gary Hufbauer, a senior fellow at the Peterson Institute for International Economics. 'Everything is now 'national security,' according to the new definition, which means it's all subject to export licenses and then they give you a license based on your contribution.' There are concerns that US trade agencies could begin charging fees to companies every time there's a meeting to discuss tariffs, according to people familiar with the matter who asked not to be identified discussing private deliberations. The Commerce Department's Bureau of Industry and Security, which issues export licenses, wasn't consulted about the revenue deal, according to people familiar with the matter who asked not to be identified discussing private conversations. Trump administration officials defend the idea as a smart way to generate revenue for the US government and suggest it will extend well beyond the chips sector. 'I think we could see it in other industries over time,' Treasury Secretary Scott Bessent said in an interview with Bloomberg Television on Wednesday. 'I think right now this is unique, but now that we have the model and the beta tests, why not expand it?' Bessent defended the deal and rejected any national-security concerns around the decision to sell Nvidia's H20 chip to China — something that had been earlier barred for fear of giving China a boost in the artificial-intelligence race. 'There are no national security concerns here,' Bessent said. 'We would not sell any of the advanced chips. So, the H20, I don't know whether you'd say they're four, five, six levels down the chips stack.' Either way, the deal highlights how Trump has pushed to open a wave of new revenue streams including by taking ownership shares of companies or extracting higher fees to live or work in the US. The US is weighing sales of a so-called 'gold card' residency permit, it won a 'golden share' to have direct say over corporate actions by United States Steel Corp., and it's secured investment pledges and potential revenue-sharing in country-level tariff talks. That's aside from the barrage of product tariffs that have at times left massive dislocations in globally traded markets. The matter further surprised China hawks in Congress, who have been unimpressed by the administration's reassurances. Rep. John Moolenaar, the Michigan Republican who chairs the US House Select Committee on China, questioned the legal basis for the move and suggested it does an end-run around controls put in place to limit the sale of sensitive technology to US adversaries. 'Export controls are a front-line defense in protecting our national security, and we should not set a precedent that incentivizes the government to grant licenses to sell China technology that will enhance its AI capabilities,' he said. It also raises questions about where the administration will steer the revenue. Trump has mused about issuing tariff rebate checks — though he has yet to seriously pursue the idea — while at other times he's said it would go toward narrowing the large budget deficit. The administration had debated launching a sovereign wealth fund before shelving those plans for now. It's too soon to say whether the administration will seek to revive the fund and steer revenue there, one official familiar with deliberations said. 'Trump's aides argue that these measures will strengthen America's AI leadership by maximizing its global influence and market share,' Hal Brands, a professor at the Johns Hopkins School of Advanced International Studies and a former Pentagon official, wrote in Bloomberg Opinion. 'Yet it is also possible that they will simply eat into America's innovation advantage.' --With assistance from Mackenzie Hawkins and Derek Wallbank. (Updates with details of consultation process in fifth paragraph.) Americans Are Getting Priced Out of Homeownership at Record Rates Dubai's Housing Boom Is Stoking Fears of Another Crash Bessent on Tariffs, Deficits and Embracing Trump's Economic Plan Why It's Actually a Good Time to Buy a House, According to a Zillow Economist The Electric Pickup Truck Boom Turned Into a Big Bust ©2025 Bloomberg L.P. Sign in to access your portfolio
Business Insider
2 hours ago
- Business Insider
Goldman Sachs Reaffirms Their Hold Rating on CoreWeave, Inc. Class A (CRWV)
In a report released today, Kash Rangan from Goldman Sachs maintained a Hold rating on CoreWeave, Inc. Class A, with a price target of $120.00. The company's shares closed today at $117.76. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Rangan covers the Technology sector, focusing on stocks such as Snowflake, Microsoft, and CoreWeave, Inc. Class A. According to TipRanks, Rangan has an average return of 6.5% and a 52.92% success rate on recommended stocks. In addition to Goldman Sachs, CoreWeave, Inc. Class A also received a Hold from Bank of America Securities's Bradley Sills in a report issued today. However, on the same day, Jefferies maintained a Buy rating on CoreWeave, Inc. Class A (NASDAQ: CRWV). Based on CoreWeave, Inc. Class A's latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $981.63 million and a GAAP net loss of $314.64 million. In comparison, last year the company earned a revenue of $116 million and had a GAAP net loss of $170.57 million
Business Wire
3 hours ago
- Business Wire
IMMUNOVANT INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Immunovant, Inc.
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--The law firm of Kahn Swick & Foti, LLC ('KSF') has commenced an investigation into Immunovant, Inc. (NasdaqGS: IMVT) ('Immunovant'). KSF is investigating whether Immunovant's officers and/or directors breached their fiduciary duties or otherwise violated state or federal laws. If you hold shares of Immunovant, Inc. (NasdaqGS: IMVT), we urge you to contact KSF to discuss your legal rights, without obligation or cost to you, by calling KSF toll-free at 1-833-938-0905, or by e-mailing KSF Managing Partner, Lewis Kahn, ( or visit to learn more. About Kahn Swick & Foti, LLC KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation's premier boutique securities litigation law firms. This past year, KSF was ranked by SCAS among the top 10 firms nationally based upon total settlement value. KSF serves a variety of clients, including public and private institutional investors, and retail investors - in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, Delaware, California, Louisiana, Chicago, New Jersey, and a representative office in Luxembourg. TOP 10 Plaintiff Law Firms - According to ISS Securities Class Action Services To learn more about KSF, you may visit
